The goal of this study is to give a brief background on the literature supporting the
PharmGKB pathway about doxorubicin action, and provides a summary of this active area of …

Simple Summary The effectiveness and safety of the anti-cancer agent doxorubicin
(anthracycline group medicine) depend on the metabolism and retention of the drug in the …

Increased understanding of the molecular mechanisms of tumor heterogeneity combined
with rapid advances in the field of pharmacogenetics and pharmacogenomics have fuelled …

DOXORUBICIN is one of the most valuable anticancer drugs in present clinical use. Its
effectiveness, however, remains restricted on two fronts: dose intensity due to acute bone …

Objectives The use of doxorubicin, a drug utilised for many years to treat a wide variety of
cancers, has long been limited due to the significant toxicity that can occur not only during …

The anthracyclines are the class of antitumor drugs with the widest spectrum of activity in
human cancers, and only a few cancers (eg, colon cancer) are unresponsive to them. The …

Anthracyclines have been important and effective treatments against a number of cancers
since their discovery. However, their use in therapy has been complicated by severe side …

Doxorubicin is an effective chemotherapeutic agent against a broad range of tumors.
However, a threshold dose of doxorubicin causes an unacceptably high incidence of heart …

A breakthrough in oncology research was the discovery of doxorubicin (Dox) in the 1960's.
Unlike other chemotherapy drugs, Dox was determined to have a greater therapeutic index …

The same doses of medication cause considerable heterogeneity in efficacy and toxicity
across human populations. Genetic factors are thought to represent important determinants …